Drugs / CAR-CLD18 T cell
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03302403 | Dec 2017 → Dec 2020 | B-cell non-Hodgkin lymphoma, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, lymphoid leukemia +1 | Kang YU | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-CLD18 T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03302403 ↗ |
| Modality | Cell therapy | “autologous T cells transduced with a chimeric antigen receptor” NCT03302403 ↗ |
| Route | Intravenous | “Route of administration: Intravenous injection.” NCT03302403 ↗ |